ValiRx

ValiRx plc wants to make a structural change in science, namely to engineer a scientific breakthrough into human health and wellbeing, through early detection of disease and therapeutic intervention. Research shows that there is a high demand for new personalised medicines and services that enhance patient care, achieve faster diagnoses, and substantially improve treatment outcomes cost effectively.

ValiRx is a growing company with a clear business model. ValiRx reduces risk in new product development through a rigorous clinical and commercial due diligence process, selecting drug candidates and technologies with evidence-based potential to address the unmet needs of the market. We aim to maximise human health sciences by adding value at the earlier stages where value increases per investment unit are the greatest.

The ValiRx management team is a mixture of entrepreneurial scientists and business professionals, all with experience in developing medical life science companies.

www.valirx.com

ValiRx Impact Report

Valirx is a biotechnology company based in London that develops diagnostics and therapeutics for cancer. We were founded in 2006 by entrepreneurial scientists with a long track record in both academic and commercial research.  Valirx wants to engineer a scientific breakthrough into human health and wellbeing through early detection of disease and therapeutic intervention. We have three core aims: enhance patient care, achieve faster diagnoses and substantially improve treatment outcomes cost effectively. We achieve these aims by developing effective therapeutic treatments and diagnostic tools for a range of diseases including cancer and neurological diseases. We have two therapeutic products in late stage, pre-clinical development. They both show promise of combating cancer safely and more effectively than currently used chemotherapeutics, hormone therapies and surgical procedures. We have also developed an innovative cancer screening test enables the detection of cancer cells in tissue samples where tumour development is only about to start. This has the potential to have a huge impact on survival rates of individuals with and at risk of developing cancer.

Read the full report

Contact ValiRx

Company Address

ValiRx
48-49 Russell Square
London
WC1B 4JP

email:

info@valirx.com

Exchange

AIM

Investor relations

www.valirx.com/investor-relations